# Efficacy and Safety of Sintilimab Combined with Nab-PP Plus Rh-endostatin in Locally Advanced/advanced and Recurrent Metastatic Squamous Non-small Cell Lung Cancer: a Single-arm, Multicenter Clinical Study

> **NCT06747169** · PHASE2 · NOT_YET_RECRUITING · sponsor: **Jian-Guo Zhou, MD, PhD** · enrollment: 32 (estimated)

## Conditions studied

- Squamous Non-Small Cell Lung Cancer SqNSCLC

## Interventions

- **DRUG:** Sintilimab, albumin-bound paclitaxel plus platinum agent (Nab-PP), and recombinant human endostatin

## Key facts

- **NCT ID:** NCT06747169
- **Lead sponsor:** Jian-Guo Zhou, MD, PhD
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2024-12-17
- **Primary completion:** 2026-12-17
- **Final completion:** 2026-12-17
- **Target enrollment:** 32 (ESTIMATED)
- **Last updated:** 2024-12-27


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06747169

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06747169, "Efficacy and Safety of Sintilimab Combined with Nab-PP Plus Rh-endostatin in Locally Advanced/advanced and Recurrent Metastatic Squamous Non-small Cell Lung Cancer: a Single-arm, Multicenter Clinical Study". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT06747169. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*